Dr Reddy’s Laboratories has welcomed the opportunity to “further progress our regulated markets journey in biosimilars,” after striking a licensing deal with Shanghai Henlius Biotech for the exclusive rights to the Chinese firm’s HLX15 proposed biosimilar to Johnson & Johnson’s Darzalex (daratumumab).
Henlius And Reddy’s Shake Hands On $130m Darzalex Biosimilar Deal
Licensing Agreement Covers US And Europe For Proposed Biosimilar To Mega-Blockbuster Daratumumab
Fresh from filing its proposed biosimilar to Perjeta with the US FDA, Henlius has brought in Dr Reddy’s Laboratories as its US and European commercial partner for its proposed biosimilar to Darzalex, which has already succeeded in Phase I trials.
More from Deals
More from Products
• By
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
• By
Fresenius Kabi has met its end of the bargain to launch biosimilars to Prolia/Xgeva in the middle of this year, after bagging FDA approvals. The German firm is also set to hear back on its filings in Europe imminently.
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).